Sally Beauty (SBH) Q3 2026 Earnings Call Transcript

Sally Beauty reported fiscal Q3 net sales of $935M (+0.2% YoY) and adjusted diluted EPS of $0.55 (+8%), helped by 60 bps gross margin expansion and $9M of pre-tax Fuel for Growth benefits. Within the mix, Sally U.S./Canada comparable sales grew 1.6% (with color +9%) while the BSG segment comparable declined 2.1% due to hair care softness and lapping K18. The company narrowed FY net sales guidance to $3.725B–$3.733B and raised adjusted EPS guidance to $2.04–$2.08, with $25M of Q3 share repurchases and $20M of term-loan repayment driving net debt leverage to 1.4x.

Analysis

SBH is still primarily a self-help story, not a clean demand inflection. The important market mechanism is that buybacks and cost-out are doing more of the EPS work than the top line, so the stock should trade on the durability of operating leverage once the current savings program rolls off. The constructive part is that the mix is shifting toward higher-velocity, higher-ASP categories and digital fulfillment that are structurally less labor-intensive, which should help defend margins even if the consumer stays price-sensitive.

The second-order risk is that the promotional backdrop is tightening at the exact moment SBH needs its care reset to work. That creates a mismatch: unit traffic can improve while gross profit dollars lag if discounting deepens, especially in care and styling tools. Over the next 1-2 quarters, BSG weakness is the cleaner tell on salon health and could stay soft if stylist discretionary spend remains cautious; over 6-18 months, the real question is whether store refreshes and LCOD can convert into sustained comp acceleration above low-single digits. The contrarian view is that the market may be underappreciating basket expansion in fragrance, nails, and BOPIS, but that optionality needs another couple of quarters of proof before it deserves a higher multiple.

Key Decisions for Investors

• Buy SBH only on post-earnings weakness or a 3%+ pullback; target a 3-6 month tactical long tied to cash returns and balance-sheet support, not top-line growth.
• If SBH rerates lower on increased promo concerns, sell 6-12 month cash-secured puts or put spreads to monetize elevated uncertainty and support entry at a better basis.
• Monitor the next print for Sally comp and BSG comp divergence; if BSG remains below -1% and care stays weak, treat SBH as a fade rather than a core long.
• Do not add aggressively until the care reset and fragrance expansion show up in hard numbers; the thesis is falsified if gross margin compresses or comps fail to improve by the next guidance update in November.